• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Oct. 31, 2017

View Archived Issues

Novartis tenders $3.9B offer for radiotherapy maker Advanced Accelerator Applications

Novartis AG has proposed buying radiopharmaceuticals specialist Advanced Accelerator Applications SA (AAA) in a deal valuing the company at $3.9 billion. The transaction would add the EU-approved neuroendocrine tumor therapy Lutathera (lutetium [177Lu] oxodotreotide) to the company's portfolio, as well as a new technology platform that Novartis said has potential applications across a number of early oncology development programs. Read More

Insys in damage control mode following arrest, stock hold

Serving as a cautionary tale for other drug companies, Insys Therapeutics Inc. is trying to right its ship after John Kapoor – its founder, former CEO and majority owner – was arrested last week on federal racketeering and fraud charges related to the off-label distribution of Subsys, a fentanyl spray approved for cancer patients with breakthrough pain. Read More

Deal with Sumitomo Dainippon for late-stage diabetes asset is 'transformative' for Poxel

LONDON – Poxel SA has landed an all-embracing deal in Asia for Imeglimin with new partner Sumitomo Dainippon Pharma Co. Ltd. taking on the costs of conducting phase III development and commercializing the first-in-class, oral, type II diabetes treatment in Japan, China and 11 other countries. Under the terms of the agreement Poxel receives an upfront payment of $42 million, plus future development and sales-based milestones of $257 million. In addition, the Lyon, France-based company will be eligible for double-digit royalties on net sales. Read More

The X4 files: Surveillance approach in IO yields win, early bid in kidney cancer

With her company "in the hunt for a series B" that could "unfold in the coming few months," X4 Pharmaceuticals Inc. CEO Paula Ragan told BioWorld that the latest data with X4P-001-IO, a C-X-C receptor type 4 (CXCR4) inhibitor, should give clear-cell renal cell carcinoma cancer patients new hope. Read More

Mutations, Wnt signaling are part of predator-prey dance

PHILADELPHIA – Understanding the evolution of cancer and discovering the most specific, immunogenic targets are crucial prerequisites for the discovery of effective therapeutics, especially when tumors continually evade immune surveillance. Read More

More precise drug, patient selection lead to increase in seamless trials

PHILADELPHIA – A growing number of therapeutics, upon showing signs of early efficacy, are moving directly into seamless registration trials, replacing the age-old phase I, II and III continuum, speeding the time to approval and potentially reaching ill patients faster. Read More

Kymera lands $30M series A to drug the 'undruggable'

Six quarters after it was co-founded, seeded and incubated by Atlas Venture, Kymera Therapeutics LLC debuted with a $30M series A round led by Atlas, with participation from Lilly Ventures and Amgen Ventures. In the words of Atlas partner Bruce Booth, co-founder and chairman, the Cambridge, Mass.-based firm is seeking to "drug the undruggable" by harnessing the power of targeted protein degradation to deliver therapeutic benefits. Read More

Financings

VBI Vaccines Inc., of Cambridge, Mass., said the underwriters of its underwritten public offering have exercised their option to purchase an additional 2.1 million shares. Read More

Other news to note

Bristol-Myers Squibb Co., of New York, reported that the EMA validated the type II variation application for Opdivo (nivolumab) to expand the current indications. The company seeks to include treating those with melanoma at high risk of disease recurrence after undergoing complete surgical resection. Read More

In the clinic

Sunovion Pharmaceuticals Inc., of Marlborough, Mass., reported post-hoc analysis of a phase III trial, as well as interim data from a long-term open-label extension study testing Latuda (lurasidone HCI) in children and adolescents with major depressive episodes associated with bipolar I disorder at a scientific meeting in Washington. Read More

News from AACR-NCI-EORTC

OBI Pharma Inc., of Taipei, Taiwan, reported preclinical results from a study of OBI-3424 in a patient-derived xenograft model of T-cell acute lymphoblastic leukemia. OBI-3424, which targets aldo-keto reductase 1c3 and releases a DNA alkylating agent, produced objective responses in eight of nine mice with a significant reduction in bone marrow infiltration at day 28 in four of six evaluable mice. Read More

News from ECTRIMS-ACTRIMS

Medicinova Inc., of La Jolla, Calif., reported top-line results from the SPRINT-MS phase IIb trial of MN-166 (ibudilast) in patients with progressive multiple sclerosis. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Vertex Pharmaceuticals discovers new PKD1 correctors

    BioWorld Science
    Vertex Pharmaceuticals Inc. has described polycystin-1 (PKD1) (mutant) correctors reported to be useful for the treatment of autosomal dominant polycystic kidney...
  • Ozempic pen and packaging

    EMA warns Ozempic linked to ‘very rare’ side effect

    BioWorld
    The EMA’s safety committee has issued a warning that the GLP-1 receptor agonist Ozempic (semaglutide, Novo Nordisk A/S) can cause an acute eye condition in which...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe